Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma

Hepatoblastoma is the most common malignant pediatric liver cancer. Histological evaluation of tumor biopsies is used to distinguish among the different subtypes of hepatoblastoma, with fetal and embryonal representing the two main epithelial components. With frequent CTNNB1 mutations, hepatoblastoma is a Wnt/β‐catenin‐driven malignancy. Considering that Wnt activation has been associated with tumor metabolic reprogramming, we characterized the metabolic profile of cells from hepatoblastoma and compared it to cells from hepatocellular carcinoma. First, we demonstrated that glucose transporter GLUT3 is a direct TCF4/β‐catenin target gene. RNA sequencing enabled to identify molecular and metabolic features specific to hepatoblastoma and revealed that several glycolytic enzymes are overexpressed in embryonal‐like compared to fetal‐like tumor cells. This led us to implement successfully three biomarkers to distinguish embryonal from fetal components by immunohistochemistry from a large panel of human hepatoblastoma samples. Functional analyses demonstrated that embryonal‐like hepatoblastoma cells are highly glycolytic and sensitive to hexokinase‐1 silencing. Altogether, our findings reveal a new, metabolic classification of human hepatoblastoma, with potential future implications for patients’ diagnosis and treatment.

[1]  C. Meisinger,et al.  ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types , 2016, Nature Communications.

[2]  P. McCrea,et al.  Beyond β-catenin: prospects for a larger catenin network in the nucleus , 2015, Nature Reviews Molecular Cell Biology.

[3]  W. Guo,et al.  MiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer , 2015, Hepatology.

[4]  S. Iwata,et al.  Structure and mechanism of the mammalian fructose transporter GLUT5 , 2015, Nature.

[5]  Chuangye Yan,et al.  Molecular basis of ligand recognition and transport by glucose transporters , 2015, Nature.

[6]  T. Strom,et al.  The genomic landscape of hepatoblastoma and their progenies with HCC-like features. , 2014, Journal of hepatology.

[7]  D. Calvisi,et al.  Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.

[8]  M. Finegold,et al.  β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. , 2014, Cancer research.

[9]  John T. Powers,et al.  Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. , 2014, Cancer cell.

[10]  Petra C. Schwalie,et al.  GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer , 2014, Cancer & Metabolism.

[11]  E. Gratton,et al.  Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer , 2014, The EMBO journal.

[12]  Petra C. Schwalie,et al.  GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer , 2014, Cancer & metabolism.

[13]  A. Thomson,et al.  Divergent LIN28-mRNA associations result in translational suppression upon the initiation of differentiation , 2014, Nucleic Acids Research.

[14]  Chao Xu,et al.  Crystal structure of the human glucose transporter GLUT1 , 2014, Nature.

[15]  S. Kosak,et al.  α-Catenin is an inhibitor of transcription , 2014, Proceedings of the National Academy of Sciences.

[16]  Yukichi Tanaka,et al.  Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium , 2014, Modern Pathology.

[17]  E. Hiyama,et al.  Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy , 2014, Current opinion in pediatrics.

[18]  J. Yates,et al.  α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes , 2013, Genes & development.

[19]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[20]  Helen M. Rowe,et al.  TRIM28 repression of retrotransposon-based enhancers is necessary to preserve transcriptional dynamics in embryonic stem cells , 2013, Genome research.

[21]  S. Chi,et al.  Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. , 2012, Cancer research.

[22]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[23]  Daria A. Gaykalova,et al.  Abstract 4097: Integrative analysis of epigenetic and transcriptional alterations in head and neck squamous cell carcinomas , 2012 .

[24]  P. Pedersen.  3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue , 2012, Journal of Bioenergetics and Biomembranes.

[25]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[26]  M. Shoshan.  3-bromopyruvate: Targets and outcomes , 2012, Journal of Bioenergetics and Biomembranes.

[27]  H. Naraba,et al.  DNA Damage–Induced Modulation of GLUT3 Expression Is Mediated through p53-Independent Extracellular Signal-Regulated Kinase Signaling in HeLa Cells , 2010, Molecular Cancer Research.

[28]  M. Delorenzi,et al.  Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. , 2010, Cancer research.

[29]  Daniel Bottomly,et al.  Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq , 2010, Nucleic acids research.

[30]  D. Rakheja,et al.  Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor , 2009, Pediatric blood & cancer.

[31]  P. Gunaratne,et al.  Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. , 2009, Human pathology.

[32]  Yu Wei,et al.  Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.

[33]  Nobuyuki Tanaka,et al.  p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.

[34]  Caroline L. Dahlberg,et al.  Crystal Structure of a β-Catenin/BCL9/Tcf4 Complex , 2006 .

[35]  A. Kiss,et al.  Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. , 2006, Human pathology.

[36]  G. Perilongo,et al.  Childhood solid tumours: a developmental disorder , 2005, Nature Reviews Cancer.

[37]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[38]  F. Brembeck,et al.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. , 2004, Genes & development.

[39]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[40]  W. Behnisch,et al.  Two novel in vitro human hepatoblastoma models, HepU1 and HepU2, are highly characteristic of fetal–embryonal differentiation in hepatoblastoma , 2003, International journal of cancer.

[41]  Guillaume Adelmant,et al.  Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 , 2001, Nature.

[42]  Marc Montminy,et al.  CREB regulates hepatic gluconeogenesis through the coactivator PGC-1 , 2001, Nature.

[43]  S. Albrecht,et al.  Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. , 1999, Cancer research.

[44]  H. Fromm,et al.  The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. , 1998, Structure.

[45]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[46]  Helen M. Rowe,et al.  TRIM 28 repression of retrotransposon-based enhancers is necessary to preserve transcriptional dynamics in embryonic stem cells , 2013 .

[47]  D. Kimelman,et al.  Crystal structure of a beta-catenin/BCL9/Tcf4 complex. , 2006, Molecular cell.

[48]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[49]  R Kemler,et al.  beta-catenin is a target for the ubiquitin-proteasome pathway. , 1997, The EMBO journal.

[50]  N. Oppenheimer,et al.  Structure and mechanism , 1989 .

[51]  the original work is properly cited. , 2022 .